{"id":"NCT00239356","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials","officialTitle":"Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-03","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2005-10-17","resultsPosted":"2014-01-10","lastUpdate":"2014-12-19"},"enrollment":119,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["Abilify","BMS-337039"]}],"arms":[{"label":"AI","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.","primaryOutcome":{"measure":"Mean Clinical Global Impression Severity Score (CGI-S) From Baseline Through End of Study- - Safety Population.","timeFrame":"Baseline to Week 348","effectByArm":[{"arm":"Aripiprazole 10 - 30 mg Once Daily (QD)","deltaMin":2.6,"sd":0.97},{"arm":"Aripiprazole 5 - 30 mg QD","deltaMin":1,"sd":0}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":20,"countries":["Canada","Croatia","Czechia","France","Hungary","Netherlands","Poland","Romania","Russia","South Africa","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Headache","Pyrexia","Nasopharyngitis","Back pain","Anxiety"]}}